Grifols, S.A. (GRFS) Income Statement

NASDAQ: GRFSRevenue, profits, margins and EPS over 5 years.

GRFS 2025 at a glance

Fiscal year ended December 31, 2025 · euros
Revenue+0.2%
€7.23B
2025 · hover or tap a bar for each year
2021: €4.93B2022: €6.06B (+22.9%)2023: €6.59B (+8.7%)2024: €7.21B (+9.4%)2025: €7.23B (+0.2%)
20212025
Gross profit−7.7%
€2.58B
2025 · hover or tap a bar for each year
2021: €1.96B2022: €2.21B (+12.8%)2023: €2.48B (+12.2%)2024: €2.79B (+12.5%)2025: €2.58B (−7.7%)
20212025
Operating income−0.4%
€1.19B
2025 · hover or tap a bar for each year
2021: €595.1M2022: €782.4M (+31.5%)2023: €782.3M (−0.0%)2024: €1.19B (+52.4%)2025: €1.19B (−0.4%)
20212025
Net income+146.1%
€386.1M
2025 · hover or tap a bar for each year
2021: €188.7M2022: €185.0M (−2.0%)2023: €42.3M (−77.1%)2024: €156.9M (+270.8%)2025: €386.1M (+146.1%)
20212025
Net profit margin+3.2 pts
5.3%
2025 · hover or tap a point for each year
2021: 3.8%2022: 3.1% (−0.8 pts)2023: 0.6% (−2.4 pts)2024: 2.2% (+1.5 pts)2025: 5.3% (+3.2 pts)
20212025

GRFS revenue and net income

RevenueNet incomeNet margin (right axis)

Where GRFS's revenue goes

2025
Revenue
€7.23B100.0%
Cost of revenue
−€4.65B−64.3%
Gross profit
€2.58B35.7%
Research & development
−€358.3M−5.0%
Sales, general & admin
−€1.06B−14.7%
Operating income
€1.19B16.4%
Interest & other expense
−€596.5M−8.3%
Income taxes
−€110.5M−1.5%
Net income
€386.1M5.3%

Each bar shows an amount and its share of revenue. GRFS kept 5.3% of revenue as net income.

GRFS profit margins

GrossOperatingNet

GRFS growth rates

to 2025
1 year3 years5 years10 years
Revenue+0.2%+6.0%——
Gross profit−7.7%+5.2%——
Operating income−0.4%+14.9%——
Net income+146.1%+27.8%——

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

GRFS income statement in euros

Grifols, S.A. annual income statement
20252024202320222021
Revenue€7.23B€7.21B€6.59B€6.06B€4.93B
Cost of revenue€4.65B€4.42B€4.11B€3.85B€2.97B
Gross profit€2.58B€2.79B€2.48B€2.21B€1.96B
Research & development€358.3M€384.0M€395.3M€361.1M€354.9M
Sales, general & admin€1.06B€1.14B€1.27B€1.11B€436.7M
Total operating expenses€1.39B€1.60B€1.70B€1.43B€1.37B
Operating income€1.19B€1.19B€782.3M€782.4M€595.1M
Interest income€34.0M€44.4M€62.3M€33.9M€11.6M
Interest expense€600.3M€773.2M€516.1M€444.5M€233.8M
Income before taxes€590.7M€444.0M€207.0M€338.0M€350.5M
Income taxes€110.5M€231.2M€43.3M€90.1M€85.1M
Net income€386.1M€156.9M€42.3M€185.0M€188.7M
EBITDA€1.62B€1.48B€1.17B€1.19B€944.0M
Gross margin35.7%38.7%37.7%36.5%39.8%
Operating margin16.4%16.5%11.9%12.9%12.1%
Net margin5.3%2.2%0.6%3.1%3.8%

Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in GRFS's financial statements (latest annual report filed April 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

GRFS financial results

In fiscal year 2025 (ended December 31, 2025), Grifols reported revenue of €7.2 billion, up 0.2% from the year before. It had net income of €386.1 million (up 146.1%), a net profit margin of 5.3%. Figures are in euros, the currency of its financial statements.

See the GRFS stock overview for the latest quote and news, or the GRFS chart for price history and technical indicators.

GRFS income statement FAQ

What is Grifols's annual revenue?

Grifols reported total revenue of €7.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 0.2% from €7.2 billion the previous year.

Is Grifols profitable?

Yes. Grifols reported net income of €386.1 million in fiscal 2025, a net profit margin of 5.3%; its operating margin was 16.4%.

What is Grifols's gross margin?

Grifols's gross margin was 35.7% in fiscal 2025: for every $100 of revenue, Grifols kept $36 after the direct cost of its products and services.

How much does Grifols spend on research and development?

Grifols spent €358.3 million on research and development in fiscal 2025, 5.0% of revenue.

When does Grifols's fiscal year end?

Grifols's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 17, 2026.

Drug Manufacturers - General income statements